ARTICLE
Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation
Masaharu Tamaki1,2, Shimpei Matsumi1,2, Hideki Nakasone1, Yuhei Nakamura1, Masakatsu Kawamura1, Shunto Kawamura1, Junko Takeshita1, Nozomu Yoshino1, Yukiko Misaki1, Kazuki Yoshimura1, Ayumi Gomyo1, Aki Tanihara1, Yosuke Okada1, Machiko Kusuda1, Kazuaki Kameda1, Shun-ichi Kimura1, Shinichi Kako1 and Yoshinobu Kanda1

© The Author(s), under exclusive licence to Springer Nature Limited 2022

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is one of auto-immune antibodies which is associated with a rare subtype of dermatomyositis (DM), and MDA5-DM is well-characterized by rapid progressive interstitial lung disease (ILD) which in part resembles pulmonary complications after allogeneic hematopoietic cell transplantation (allo-HCT). However, previous studies about anti-MDA5 antibody after allo-HCT were extremely limited. Here, we present 4 cases of ILD with anti-MDA5 antibody after allo-HCT. All of the cases showed rapidly progressive clinical course and 3 of 4 cases died despite intensive immunosuppressive therapies which included prednisolone, cyclophosphamide and calcineurin inhibitor. Additionally, 3 of 4 cases had tested positive for anti-MDA5 antibody by using cryopreserved plasma which were collected about 2–3 months before the diagnosis of MDA5-DM-ILD. It suggests that an inflammatory condition due to MDA5-DM-ILD might have sub-clinically occurred before the development of respiratory failure. The current cases suggest that the clinical feature was relatively similar to classical MDA5-DM-ILD, although it is difficult to distinguish MDA5-DM-ILD from chronic GVHD and other pulmonary complications after allo-HCT. Since clinical courses of MDA5-DM-ILD is considerably aggressive, it is important to discriminate MDA5-DM-ILD from other complications after allo-HCT.

INTRODUCTION
Non-infectious pulmonary complications include various disease entities, leading to fatal diseases after allogeneic hematopoietic cell transplantation (allo-HCT) [1–6]. However, a distinct definition of these complications has not been clearly described, since the diagnosis of non-infectious pulmonary complications is mainly based on the exclusion of other diseases [7]. Bronchoscopy is a promising diagnostic procedure for distinguishing other pulmonary disease [5, 8, 9], but a considerable number of allo-HCT recipients are difficult to receive bronchoscopy due to their critically ill state. Therefore, clinically diagnosed pulmonary complications include heterogeneous manifestations and disease origins due to the limitation of diagnostic procedures.

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is one of auto-immune antibodies which is associated with a rare subtype of dermatomyositis (DM) [10–12]. MDA5-DM is well-characterized by mucocutaneous lesion, amyopathic or hypomyopathic muscle involvement and rapidly progressive interstitial lung disease (ILD) [13]. Prognosis of MDA5-DM is devastating and the 6-months survival rate was reported as 33–66% in the previous studies [14–17]. The symptoms of pulmonary complications after allo-HCT in part resemble MDA5-DM-related ILD. However, previous studies about anti-MDA5 antibody after allo-HCT were extremely limited [18, 19]. Here, we present 4 cases of ILD with anti-MDA5 antibody after allo-HCT and analyzed the clinical courses in detail including the serial changes in anti-MDA5 antibody titers and possible association with Coronavirus disease 2019 (COVID-19) pandemic.

PATIENTS AND METHODS
Patients
We reviewed clinical charts of 504 patients who underwent allo-HCT at our center between June 2007 and December 2021. Among them, all the patients who diagnosed as MDA5-DM-ILD after the allo-HCT were included in this study. This study was approved by the Institutional Review Board of Jichi Medical University Saitama Medical Center and performed in accordance with the Declaration of Helsinki and its later amendments. Informed consent for using samples was obtained from each patient.

Serological tests of the cases
The patients’ plasma was prospectively cryopreserved on the day before the commencement of conditioning regimen, day 30, 60, 90, 120, 180, 270 and 360 after the allo-HCT. Additional cryopreservation was performed based on each physician’s discretion. The plasma was used for measurement of anti-MDA5 antibody and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG. Anti-MDA5 antibody was

1 Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. 2 These authors contributed equally: Masaharu Tamaki, Shimpei Matsumi.
3 Email: ycanda-tky@umin.ac.jp

Received: 9 March 2022 Revised: 11 May 2022 Accepted: 26 May 2022
Published online: 4 June 2022
measured with ELISA and SARS-CoV-2 IgG was measured with CLEIA. The upper limit of the available value of anti-MDA5 antibody was 150. These tests were commercially performed by SRL, inc., Japan.

RESULTS
Clinical courses of the MDAS-DM-ILD cases
Among 504 patients, there were 60 ILD cases who had unidentifiable origin, and the cryopreserved plasma at the diagnosis of ILD was available from the 35 of 60 cases. Among the cases, we identified 4 cases of MDAS-DM-ILD during the study period. All of the cases were diagnosed during the clinical course, and any other MDAS-DM-ILD cases could not be found based on the review of cryopreserved samples. Median age at the onset of MDAS-DM-ILD was 45 years (34–61). Median duration between the onset of MDAS-DM-ILD and the latest allo-HCT was 234 days (134–469). One of the cases developed MDAS-DM-ILD after the second allo-HCT, and a duration between the onset and the first allo-HCT was 1410 days. Median follow-up duration was 90 days (49–291), and 3 of 4 cases died.

Case 1
A 60-year-old female was diagnosed as myelodysplastic syndrome with excess blast-2 (MDS-EB2). After 3 cycles of azacytidine, bone marrow aspiration revealed complete remission (CR), and she underwent allo-HCT from an HLA-matched unrelated donor. The summary of allo-HCT was shown in Table 1. She developed skin GVHD on day 28 and gut GVHD on day 58 of the allo-HCT. The maximum grade of acute GVHD was grade II. She was treated with prednisolone (PSL) from day 60. Acute GVHD gradually ameliorated, and the administration of PSL and cyclosporine was terminated 11 months from allo-HCT.

Six weeks after the end of immunosuppressive therapy, she developed lichen planus like skin, skin rash, non-specific mucositis, arthritis and elevation of liver enzyme (gamma-glutamyl transpeptidase and alkaline phosphatase were predominant). She was clinically diagnosed as chronic GVHD without biopsy, and cyclosporine was restarted. However, she gradually suffered from dyspnea. She was emergently hospitalized after 2 weeks due to severe respiratory dysfunction, and was immediately intubated and transferred to intensive care unit (ICU). The images of lung computed tomography (CT) revealed diffuse bilateral ground glass opacity (GGO), suggesting immune-related pathogenesis (Fig. 1a). The day after admission, a steroid pulse therapy with methyl-PSL 1 g/day × 3 days and a subsequent tapering phase was performed. One week after the admission, she revealed to test positive for anti-MDA5 antibody. However, her respiratory condition was slightly improved. One week later, she underwent allo-HCT from an HLA-matched unrelated donor. The summary of allo-HCT was shown in Table 1. She developed skin GVHD on day 28 and gut GVHD on day 58 of the allo-HCT. The maximum grade of acute GVHD was grade II. She was treated with prednisolone (PSL) from day 60. Acute GVHD gradually ameliorated, and the administration of PSL and cyclosporine was terminated 11 months from allo-HCT.

Six weeks after the end of immunosuppressive therapy, she developed lichen planus like skin, skin rash, non-specific mucositis, arthritis and elevation of liver enzyme (gamma-glutamyl transpeptidase and alkaline phosphatase were predominant). She was clinically diagnosed as chronic GVHD without biopsy, and cyclosporine was restarted. However, she gradually suffered from dyspnea. She was emergently hospitalized after 2 weeks due to severe respiratory dysfunction, and was immediately intubated and transferred to intensive care unit (ICU). The images of lung computed tomography (CT) revealed diffuse bilateral ground glass opacity (GGO), suggesting immune-related pathogenesis (Fig. 1a). The day after admission, a steroid pulse therapy with methyl-PSL 1 g/day × 3 days and a subsequent tapering phase was performed. One week after the admission, she revealed to test positive for anti-MDA5 antibody. However, her respiratory condition was slightly improved. One week later, she underwent allo-HCT from an HLA-matched unrelated donor. The summary of allo-HCT was shown in Table 1. She developed skin GVHD on day 28 and gut GVHD on day 58 of the allo-HCT. The maximum grade of acute GVHD was grade II. She was treated with prednisolone (PSL) from day 60. Acute GVHD gradually ameliorated, and the administration of PSL and cyclosporine was terminated 11 months from allo-HCT.

Case 2
A 32-year-old female was diagnosed as acute myeloid leukemia (AML) with RUNX1-RUNX1T1 and was treated with idarubicin/cytarabine (Ara-C) as induction therapy followed by 3 cycles of high-dose Ara-C. However, she experienced AML relapse 4 months after the completion of chemotherapy. She was re-treated with induction chemotherapy including mitoxantrone, etoposide and Ara-C. She achieved CR state and underwent allo-HCT from an HLA-matched unrelated donor.

An autopsy revealed the diffuse alveolar damage with fibrosis and lymphocyte infiltration which were compatible with MDAS-DM-ILD. Dermis and pectoral muscle also showed slight lymphocytic infiltration which was consistent with DM.

Case 3
A 32-year-old female was diagnosed as acute myeloid leukemia (AML) with RUNX1-RUNX1T1 and was treated with idarubicin/cytarabine (Ara-C) as induction therapy followed by 3 cycles of high-dose Ara-C. However, she experienced AML relapse 4 months after the completion of chemotherapy. She was re-treated with induction chemotherapy including mitoxantrone, etoposide and Ara-C. She achieved CR state and underwent allo-HCT from an HLA-matched unrelated donor.

An autopsy revealed the diffuse alveolar damage with fibrosis and lymphocyte infiltration which were compatible with MDAS-DM-ILD. Dermis and pectoral muscle also showed slight lymphocytic infiltration which was consistent with DM.

Case 4
A 32-year-old female was diagnosed as acute myeloid leukemia (AML) with RUNX1-RUNX1T1 and was treated with idarubicin/cytarabine (Ara-C) as induction therapy followed by 3 cycles of high-dose Ara-C. However, she experienced AML relapse 4 months after the completion of chemotherapy. She was re-treated with induction chemotherapy including mitoxantrone, etoposide and Ara-C. She achieved CR state and underwent allo-HCT from an HLA-matched unrelated donor.

An autopsy revealed the diffuse alveolar damage with fibrosis and lymphocyte infiltration which were compatible with MDAS-DM-ILD. Dermis and pectoral muscle also showed slight lymphocytic infiltration which was consistent with DM.

Case 5
A 32-year-old female was diagnosed as acute myeloid leukemia (AML) with RUNX1-RUNX1T1 and was treated with idarubicin/cytarabine (Ara-C) as induction therapy followed by 3 cycles of high-dose Ara-C. However, she experienced AML relapse 4 months after the completion of chemotherapy. She was re-treated with induction chemotherapy including mitoxantrone, etoposide and Ara-C. She achieved CR state and underwent allo-HCT from an HLA-matched unrelated donor. The summary of allo-HCT was shown in Table 1. She developed skin GVHD on day 28 and gut GVHD on day 58 of the allo-HCT. The maximum grade of acute GVHD was grade II. She was treated with prednisolone (PSL) from day 60. Acute GVHD gradually ameliorated, and the administration of PSL and cyclosporine was terminated 11 months from allo-HCT.
HLA-matched related donor (Table 1). Three months later, she was complicated with moderate bronchiolitis obliterans, and was given a treatment with inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist. Since a copy number of RUNX1-RUNX1T1 was increased 22 months after allo-HCT, she received 3 times of donor lymphocyte infusion. However, she developed extramedullary mass of AML in front of chest and the right upper lobe of lung 3 years after allo-HCT. She was treated with radiotherapy, 1 cycle of high-dose Ara-C and 1 cycle of a combination therapy with Ara-C, aclacinomycin and gemtuzumab ozogamicin. She achieved CR state and underwent the second allo-HCT from an HLA-matched unrelated donor (Table 1).

She developed hepatic and mucosal chronic GVHD 6 months after the second allo-HCT, while a copy number of RUNX1-RUNX1T1 increased 7 months after the second allo-HCT. Eight months later from the second allo-HCT, she suffered from cough and skin rashes of fingers and face, and respiratory dysfunction with 1–2 L/min of oxygen demand. Lung CT showed bilateral sporadic GGO and she tested positive for anti-MDA5 antibody, resulting in the start of 10 mg/day of PSL (Fig. 1b). At the same time, she was hospitalized at our center due to the regrowth of extramedullary mass of AML in a lung spine. A treatment for AML preceded an intervention for MDAS-DM-ILD, and she received radiotherapy for extramedullary mass. After the completion of radiotherapy, a treatment for ILD was commenced. Due to a concern of AML recurrence, an intensive immunosuppressive therapy was avoided. On the day 24 of the admission, an intervention by 1 mg/kg of PSL and cyclosporine was commenced, and her respiratory condition was slightly improved. However, she developed pressing feeling in chest 49 days after the admission, and lung CT on the day 53 revealed pneumothorax on the right chest and pneumomediastinum (PNM) (Fig. 1c). Her respiratory condition gradually deteriorated and CT scan on the day 71 after the admission showed exacerbation of the pneumothorax. She was treated with CY with 500 mg/m² on the day 75 and with 750 mg/m² on the day 89 after the admission, but her respiratory condition had not been improved. Although she received surgical drainage of mediastinum for reducing mass effect of PNM on the day 92 of the admission, her respiratory condition became worse, leading to intubation and transfer to ICU. Her respiratory condition was further exacerbated and veno-venous extracorporeal membrane oxygenation was initiated. An additional dose of 1000 mg/m² of CY was administrated 103 and 117 days after the admission. However, her respiratory condition was not improved and she died on the day 131 after the admission (Table 2).

Case 3
A 33-year-old male was diagnosed as AML with KMT2A-MLLT1 and was treated with idarubicin/Ara-C followed by 3 cycles of high-dose Ara-C. After the chemotherapy, he achieved CR state, and underwent allo-HCT from an HLA-matched related donor (Table 1). Although he developed skin acute GVHD 25 days after allo-HCT, GVHD was rapidly improved with topical steroid. He developed infectious pneumonia 6 months after allo-HCT, and was treated with antibiotics for 2 weeks. Since he was also complicated with organizing pneumonia and lung CT showed patchy GGO, 0.5 mg/kg of PSL was also added and subsequently tapered gradually.

He suffered from dyspnea 7 months after allo-HCT, and lung CT after 8 months revealed an exacerbation of bilateral GGO (Fig. 1d). He showed mild respiratory dysfunction with peripheral capillary hemoglobin oxygen saturation 94–95% at room air, and needed 2–4 L/min of oxygen supplementation. At the same time, he revealed to test positive for anti-MDA5 antibody, and cyclosporine was increased from 10 mg/day to 150 mg/day. He did not experience skin rash lesion. One week later, he was hospitalized at our center for the treatment of MDAS-DM-ILD with steroid pulse therapy. After the completion of steroid pulse, he was treated with 7 doses of CY as following: 500 mg/m² on day 7, 750 mg/m² on day 23, 1000 mg/m² on days 37 and 51, 500 mg/m² on days 76, 92 and 134 of the admission. Due to nausea and liver enzyme elevation, the dose of 5–7th CY was reduced. Although his respiratory condition was gradually improved after the second administration of CY, CT scan revealed PNM on day 15 and pneumothorax on the right chest on day 49 of the admission. Since he developed right chest pain and exacerbation of dyspnea and pneumothorax (Fig. 1e), he received surgical drainage of the right chest on the day 58 of the admission. After the operation, his respiratory condition was improved, although he needed oxygen supplementation of 1 L/min at a rest and 1–2 L/min at an effort. He initiated home oxygen therapy and discharged at the day 136 of
Table 2. Summary of MDA5-DM-ILD

| Onset Preceding event | CT findings of the MDA5-DM-ILD cases | Respiratory condition at the onset | Treatment | Outcome |
|-----------------------|-------------------------------------|----------------------------------|-----------|---------|
| Case 1 15 months from allo-HCT | Bilateral GGO | SpO2 85% (RA), RR 21/min, immediately intubated | PSL/CY/TAC/TOF | Died |
| Case 2 8 months from 2nd exacerbation of chronic GVHD | Bilateral GGO, pneumomediastinum | SpO2 97% (RA), RR 24/min | PSL/CY/CsA | Died |
| Case 3 8 months from allo-HCT | Bilateral GGO | SpO2 95% (RA), RR 30/min | PSL/CY/CsA | Alive |
| Case 4 4 months from allo-HCT | Termination of CsA | SpO2 92% (RA), RR 20/min | PSL/CY/CsA | Died |

MDA5-DM-ILD melanoma differentiation-associated gene 5 dermatomyositis interstitial lung disease, MDA5-DM is one of rare but distinct subtype of clinically amyopathic DM which is predominantly observed in east Asia.

Case 4
A 51-year-old male was diagnosed as AML with RUNX1-RUNX1T1 and treated with idarubicin/Ara-C as induction therapy followed by 3 cycles of high-dose Ara-C. However, AML recurred 6 months after the completion of chemotherapy. Although he had been treated with 1 cycle of high-dose Ara-C and 1 cycle of combination therapy with Ara-C and gemtuzumab ozogamicin, he did not achieve CR state after these treatments. He was additionally treated with a standard-dose of AraC as a cyto-reductive therapy and subsequently received a conditioning regimen including BU and CY, followed by allo-HCT from an HLA-matched unrelated donor (Table 1). A bone marrow aspiration on day 27 revealed that he achieved molecular CR. Although he was complicated with skin acute GVHD for 28 days after allo-HCT, GVHD was gradually improved with topical steroid. His cyclosporine was discontinued on the day 113.

He suffered from dyspnea 4 months after allo-HCT, and lung CT revealed an exacerbation of bilateral GGO (Fig. 1f). He showed mild to moderate respiratory dysfunction with 92% of peripheral capillary hemoglobin oxygen saturation at room air. He did not demonstrate definite skin rash lesions. Although he was given a treatment with a broad-spectrum antibiotic, his respiratory condition was not improved. Therefore, PSL 1 mg/kg was administrated from the day 3 of the admission. On the day 6, he revealed to test positive for anti-MDA5 antibody. Based on the detection, a combination therapy of steroid, cyclosporine and CY was commenced immediately. CY was administrated as following: 500 mg/m² on day 7, 1000 mg/m² on day 15, and 500 mg/m² on days 29 and 43 of the admission. Since his respiratory state deteriorated drastically, steroid pulse therapy (methyl-PSL 1 g/day for 3 days) was also added on day 16 and day 29. Despite the combination therapy, his respiratory condition deteriorated, leading to an intubation and transfer to ICU on day 29. He died on day 51 of the admission.

Serological findings of the MDAS-DM-ILD cases
We additionally measured anti-MDA5 antibody with cryopreserved plasma of the 4 cases at several time points during the clinical courses (Fig. 2). The higher titers of anti-MDA5 antibody than the upper limit was detected in Cases 1 and 2. Anti-MDA5 antibody had been detected 43–99 days before the diagnosis of their ILD in all of the cases except Case 4. After the commencement of treatment, the titer of anti-MDA5 antibody had declined in Case 3 and Case 4. Although the titers of anti-MDA5 antibody might have declined also in Case 1 and Case 2, the tendency was not evaluated due to the considerably high titers of the 2 cases.

In addition, we experienced 3 cases of MDAS-DM-ILD in 2021, whereas there was only 1 case before 2020 at our center. Considering about the reason about the incidence, COVID-19 pandemic is one of differences between the periods before and after 2020. Therefore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG was also measured using cryopreserved plasma at the diagnosis of MDAS-DM-ILD for the purpose of exploring the association between the detection of anti-MDA5 antibody and the viral pandemic. Case 4 showed a positive result of SARS-CoV-2 IgG, while the other two cases tested negative. Case 4 had not developed any definite symptoms related to COVID-19 during the whole clinical course.

DISCUSSION
MDAS-DM is one of rare but distinct subtype of clinically amyopathic DM which is predominantly observed in east Asia.
Clinical features of this disease entity include distinctive mucocutaneous lesion, ILD, arthritis, fever, hand swelling and PNM [20]. ILD due to MDA5-DM is generally rapidly progressive and the survival prognosis is unfavorable despite various intensive immunosuppressive therapies [14, 15, 21, 22]. Radiological findings of MDA5-DM-ILD have not been fully elucidated. One of previous studies reported that majority of MDA5-DM-ILD patients showed an unclassifiable pattern which was a mixture of consolidation and GGO [23], while another study reported that 74.2% of MDA5-DM-ILD showed an organizing pneumonia pattern [24]. PNM was also a unique radiological finding of MDA5-DM-ILD, and the prognosis of MDA5-DM-ILD with PNM was unfavorable (1y-OS 40%) [25]. Although an appropriate risk stratification and treatment are important to overcome the inferior prognosis, treatment strategies are mainly based on clinical experiences and expert opinions due to the paucity of clinical evidence [26]. In Japan, “triple therapy” is a widely accepted treatment for MDA5-DM-ILD which includes high-dose glucocorticoid, tacrolimus and cyclophosphamide [16]. The combination therapy showed significantly the higher 6-months survival rate than control group (89% vs 33%, P < 0.001).

All of the 4 cases in this study showed rapidly progressive clinical courses and 3 of them died within 5 months despite the intensive immunosuppressive therapy. Their main radiological findings were GGO and PNM. Two of 4 cases showed skin rashes, while no case developed typical mucocutaneous ulcer. Overlap of skin chronic GVHD might make it difficult to distinguish DM related skin lesion from GVHD. Since the current study was based on retrospective review of clinical charts, actual findings of skin lesions could not be confirmed. All of the 4 cases were treated with a combination treatment including high-dose corticosteroid, calcineurin inhibitor and cyclophosphamide based on the previous study [16]. In case 1, tofacitinib, a JAK inhibitor, was additionally administered due to refractoriness to the combination therapy [27]. Clinical features of MDA5-DM-ILD after allo-HCT in this study was relatively comparable with classical MDA5-DM-ILD except skin involvement and more rapid progression of ILD. Since a previous study of MDA5-DM after allo-HCT by dermatologists showed typical skin lesion such as palmar violaceous papules and digital ulcerations [18], the lack of detail cutaneous examination might be a reason of discrepancy between the current and previous reports. The clinical course of MDA5-DM-ILD seems to be more aggressive than other pulmonary complications after allo-HCT. Moreover, MDA5-DM-ILD after allo-HCT also seems to be more rapidly progressive than de novo MDA5-DM-ILD. Therefore, it is important to distinguish MDA5-DM-ILD from other complications.

MDA5 is a member of retinoic acid inducible gene I like receptors which is binding with viral RNAs. When a viral infection occurs, viral RNAs trigger MDA5. Activated MDA 5 interact with the adaptor mitochondrial antiviral signaling protein, leading to the transcription of the genes encoding type I interferons [28]. Since MDA5 acts as a receptor of viral RNAs, preceding infection might be one of the causes of MDA5-DM. Seasonal and residential clustering of the disease supports this hypothesis [29, 30]. Case 3 in this study developed pneumonia before MDA5-DM-ILD, and it might have affected the occurrence of MDA5-DM-ILD. Additionally, SARS-CoV-2 might be a trigger of MDA5-DM-ILD. SARS-CoV-2 is detected by MDA5 and induces subsequent interferon responses [31–33]. A similarity of clinical features between MDA5-DM-ILD and COVID-19 also suggests a relationship between these diseases [34–36]. Since Case 4 tested positive for SARS-CoV-2 IgG, asymptomatic SARS-CoV-2 infection might have affected the incidence of MDA5-DM-ILD in the case. Moreover, cellular RNAs also trigger MDA5 in several settings such as autoimmune inflammatory diseases and cancer treatments [28]. Auto/allo-immune pathogenesis of chronic GVHD might affect the occurrence of MDA5-DM after allo-HCT.

Human leukocyte antigen (HLA) is another factor which might be related with the incidence of MDA5-DM-ILD. In a Japanese cohort study, HLA-DRB1* 01:01 and DRB1* 04:05 were reported to be associated with susceptibility to MDA5-DM-ILD [37]. Since these HLA alleles are frequently observed in Japanese population, it might be a reason why MDA5-DM is often seen in East Asia. Case 3 in this study also had the allele of HLA-DRB1* 04:05, which might be associated with the occurrence of MDA5-DM-ILD.

In addition to the diagnosis, anti-MDA5 antibody might be utilized for monitoring MDA5-DM-ILD. Although titers of anti-MDA5 antibody at a diagnosis were not associated with severity of MDA5-DM-ILD [38], titers of the antibody after treatments were correlated with survival and relapse of ILD [39]. In our case series, 2 of 4 cases showed declining titers of anti-MDA5 antibody, and 1 case has still been alive despite the severe respiratory failure. Moreover, 3 of 4 cases had tested positive for anti-MDA5 antibody about 2–3 months before the diagnosis of MDA5-DM-ILD. Since Case 2 and 3 were complicated with bronchiolitis obliterans or infectious pneumonia, these pulmonary complications might have
made it difficult to distinguish MDA5-DM-ILD from other pulmonary diseases. However, Case 1 had not shown any definite pulmonary complications before the development of MDA5-DM-ILD. Therefore, it suggests that an inflammatory condition due to MDA5-DM-ILD might have sub-clinically occurred before the development of respiratory failure.

In conclusion, we experienced 4 cases of MDA5-DM-ILD. All cases showed rapidly progressive clinical course, and 3 of them died within very short duration despite the intensive immunosuppressive therapy. The clinical feature was relatively similar to classical MDA5-DM-ILD, although it is difficult to distinguish MDA5-DM-ILD from the other immune and infectious pulmonary complications after allo-HCT. Since clinical courses of MDA5-DM-ILD is considerably aggressive, it is important to discriminate MDA5-DM-ILD from other complications after allo-HCT.

DATA AVAILABILITY
Please contact the corresponding author or Masaharu Tamaki (Division of Hematology, Jichi Medical University Saitama Medical Center. E-mail: m.tamaki.221@gmail.com).

REFERENCES
1. Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Rivière F, et al. Noninfectious lung complications after allogeneic hematopoietic stem cell transplantation. Eur Respir J. 2018;51. https://doi.org/10.1183/13993003.0266-2017
2. Broglio L, Fretham C, Al-Seraify A, George B, Kurtzberg J, Loren A, et al. Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:2024–30. https://doi.org/10.1016/j.bbmt.2019.06.004.
3. Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transpl. 2019;54:383–92. https://doi.org/10.1038/s41409-018-0266-6.
4. Alesza B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;28:425–34. https://doi.org/10.1038/sj.bmt.1701342.
5. Zhang Z, Wang C, Peters SG, Hogan WJ, Hashmi SK, Litzow MR, et al. Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest 2021;159:2325–33. https://doi.org/10.1016/j.chest.2021.01.008.
6. Adachi Y, Ozeki K, Utkai S, Sagou K, Fukushima N, Kohno A. Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2019;109:700–10. https://doi.org/10.1007/s12185-019-02643-9.
7. Panoskaltsis-Mortari A, Greisen M, Madtes DK, Belperio JA, Haddad IV, Folz RJ, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183:1262–79. https://doi.org/10.1164/rccm.201107-1125RE.
8. Ziliotto J, Smith C, Kosyca B, Maundrell A, Bardy P, et al. Inflammatory myopathies after allogeneic stem cell transplantation. Muscle Nerve. 2018;58:790–5. https://doi.org/10.1002/mus.26341.
9. Kurtzman DJB, Vleugels RA. Non-infectious differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78:776–83. https://doi.org/10.1016/j.jaad.2017.12.010.
10. Jiang L, Wang Y, Peng Q, Shu X, Wang G, Wu X. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol. 2019;38:1655–63. https://doi.org/10.1007/s10025-019-01445-w.
11. Lepelletier C, Bengouf D, Lyes Z, de Masson A, Chasset F, Jachiet M, et al. Dermatopoietic Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatol. 2017;153:184–8. https://doi.org/10.1001/jamadermatol.2016.5397.
12. Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol. 2021;60:293–304. https://doi.org/10.1007/s12016-020-08822-5.
13. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol (Oxf). 2019;57:1278–84. https://doi.org/10.1093/rheumatology/kez158.
14. Goto T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol (Oxf). 2012;51:11563–70. https://doi.org/10.1093/rheumatology/kes102.
15. Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5 Positive Dermatomyositis. Arthritis Rheumatol. 2020;72:488–98. https://doi.org/10.1002/art.41105.
16. Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment, Rheumatol (Oxf). 2020;59:3284–92. https://doi.org/10.1093/rheumatology/keaa123.
17. Liu W, Guo L, Fu Y, Zhao P, Yang H, et al. Clinical outcomes of organizing pneumonia following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54:1533–45. https://doi.org/10.1038/s41409-019-2045-7.
18. Horami H, Fujisawa T, Nakashima R, Johokoh H, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–99. https://doi.org/10.1016/j.rmed.2016.01.019.
19. Zhou M, Ye Y, Yan N, Lian X, Bao C, Guo Q. Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediatinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin Rheumatol. 2020;39:1919–27. https://doi.org/10.1007/s12006-019-04918-2.
20. Rios-Padros-Franco B, Díaz Del Campo F, Trallero-Aragüas E, Ruiz-Rodríguez JC, Castelli I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of melanoma differentiation-associated gene 5 positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50:776–90. https://doi.org/10.1016/j.semarthrit.2020.03.007.
21. Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019;381:291–3. https://doi.org/10.1056/NEJMoa1900405.
22. Dias Junior AG, Sampaio NG, Rehwinkel J. A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2019;27:775–85. https://doi.org/10.1016/j.trendsmb.2018.08.007.
23. Nishina N, Sato S, Masui K, Goto T, Kusunaga K, Tsurumaki N, et al. Seasonal and residential clustering of anti-MDA5 antibody. Clin Rheumatol. 2011;30:1480–4. https://doi.org/10.1007/s12006-011-1228-1.
24. Kawasaki Y, Suzuki H, Hori S, Nishida K, et al. Anti-MDA5 autoantibodies in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Res. 2005;5:25-32. https://doi.org/10.1080/12296660590871698.
25. Yang Y, Goto K, Zhang D, et al. The RIG-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatol (Oxf). 2010;49:433–40. https://doi.org/10.1093/rheumatology/kep375.
33. Sampaio NG, Chauveau L, Hertzog J, Bridgeman A, Fowler G, Moonen JP, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep. 2021;11:13638 https://doi.org/10.1038/s41598-021-92940-3.

34. Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41:1021–36. https://doi.org/10.1007/s00296-021-04819-1.

35. Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep. 2021;23:63 https://doi.org/10.1007/s11926-021-01023-9.

36. Giannini M, Ohana M, Nespoli B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;56. https://doi.org/10.1183/13993003.01618-2020

37. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64:3736–40. https://doi.org/10.1002/art.34657.

38. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. J Rheumatol. 2017;44:319–25. https://doi.org/10.3899/jrheum.160662.

39. Matsushita T, Mizumaki K, Kano M, Yagi N, Tenmichi M, Takeuchi A, et al. Anti-melanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176:395–402. https://doi.org/10.1111/bjd.14882.

AUTHOR CONTRIBUTIONS
MT and SM conceived the original idea and collected the data. MT wrote the manuscript. HN and YK advised on methods and wrote the manuscript. YN, MK, S.Kawamura, JT, NY, YM, KY, AG, AT, YO, MK and KK collected the data. SIK and SKako collected the data and contributed to critical revision of the manuscript. All authors approved the final version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Yoshinobu Kanda.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.